# The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis

> **NCT04269954** · PHASE4 · UNKNOWN · sponsor: **Capital Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Cerebral Venous Sinus Thrombosis
- Batroxobin

## Interventions

- **DRUG:** Batroxobin combined with low molecular weight heparin

## Key facts

- **NCT ID:** NCT04269954
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04269954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04269954, "The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT04269954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*